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Purpose: This study was undertaken to determine the incidence of disease progression of 
moderate (50% to 79%) internal carotid artery stenosis in patients with symptoms, 
patients with nonhemispheric symptoms, and symptom-free patients and to define the risk 
of development of new neurologic events in each group. 
Methods: Over a 6-year period, 272 patients with moderate internal carotid artery stenoses 
were monitored for a mean of 44 months with color-flow duplex scanning (CFS). At the 
time of the initial scan, 142 patients were symptom free, 87 had experienced transient 
ischemic attacks, amaurosis fugax, or mild strokes, and 43 had ill-defined nonhemispheric 
symptoms. The average number of follow-up scans was 2.4 per patient (range 1 to 11). 
Results: During follow-up, 23 (26%) of the patients with symptoms, 17 (40%) of the 
patients with nonhemispheric symptoms, and 30 (21%) of the symptom-free patients had 
development of additional neurologic symptoms. Life-table comparison of ipsilateral 
ischemic events showed a significantly (p = 0.03) higher cumtdative rate in the 
symptomatic group (20%) than in the asymptomatic group (7%) at 2 years. Mean annual 
stroke rates were 6% and 2% in patients in the symptomatic and asymptomatic groups, 
respectively. None of the patients in the nonhemispheric group had a stroke within 4 years 
of the initial study. Disease progression occurred in 16% of the patients. In the 
asymptomatic group, ipsilateral stroke occurred more frequently (p = 0.0001) in patients 
with disease progression (25%) than in patients with stable lesions (1%). CFS detected 
disease progression in 19 (79%) of 24 patients before the artery occluded or stroke 
occurred. In patients with symptoms, stroke was more frequent (p = 0.02) in patients 
with six or more risk factors (29%) than in those with five or fewer risk factors (7%). 
Conclusion: Although the risk of stroke is less in patients with moderate stenosis than it 
is in patients with severely stenotic lesions, symptom-free patients with advancing disease 
and patients with symptoms and multiple risk factors are at increased risk for development 
of neurologic events. These findings support he use of CFS to monitor patients with 
carotid artery disease and suggest hat a more aggressive surgical approach may be 
indicated in selected patients with moderate carotid artery stenosis. (J VASe SURG 
1995;21:346-57.) 
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Recent multicenter t ials in North America and 
Europe have unequivocally confirmed the high risk of 
stroke at 2 and 3 years in patients with symptomatic 
70% to 99% diameter-reducing stenoses of  the 
internal carotid artery (ICA) who were treated with 
aspirin therapy. 1,2 Similarly, results from the Veter- 
ans Administration (VA) asymptomatic arotid 
artery trial showed that patients with less severe 1CA 
stenoses ( ___ 50%) who received aspirin therapy alone 
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Table I. Patient characteristics and risk factors 
Symptomatic Nonhemispheric Asymptoma#c p Value 
Patients 87 43 142 
Age 68.7 -+ 8.1 71.1 -+ 8.4 68.6 +_ 8.7 >-0.10 
Sex 
Men 49 (56%) 19 (44%) 72 (51%) 0.4I 
Women 38 (44%) 24 (56%) 70 (49%) - 
Risk factors 
Hypertension 74 (85%) 36 (84%) 126 (89%) 0.59 
Diabetes 28 (32%) 9 (21%) 49 (35%) 0.24 
CAD-MI 58 (67%) 27 (63%) 87 (61%) 0.71 
PVD 38 (44%) 14 (33%) 76 (54%) 0.04 
Smoking 57 (66%) 30 (70%) 97 (68%) 0.86 
Hyperlipidemia 42 (48%) 20 (47%) 74 (52%) 0.75 
Atrial fibrillation 22 (25%) i0 (23%) 20 (14%) 0.08 
Aspirin 58 (67%) 28 (65%) 103 (73%) 0.51 
CAD-M/, Coronary artery disease and myocardial infarction; PVD, peripheral vascular disease. 
had a higher isk for development ofan adverse neu- 
rologic event han did patients who received aspirin 
and underwent carotid endarterectomy (CEA).a 
Although these trials confirmed the success of 
CEA in decreasing the risk of early stroke and 
documented the dismal natural history of high-grade 
ICA stenoses in patients with symptomatic and 
asymptomatic stenoses, several controversial issues 
persist. Specifically, the proper management of less 
severe ICA lesions (50% to 79% diameter-reducing 
stenoses) remains unclear, in part because of the 
uncertainty hat exists regarding the natural history of 
these lesions and whether the outcomes from the 
North American Symptomatic Carotid Endarterec- 
tomy Trial (NASCET) and the European Carotid 
Surgery Trial (ECST) can be extrapolated to carotid 
artery stenoses of moderate severity) Therefore our 
purpose in this retrospective study was to investigate 
the natural history of moderate (50% to 79%) ICA 
stenosis in patients in both symptomatic and asymp- 
tomatic groups and to determine whether progres- 
sion of disease to a high-grade stenosis or total 
occlusion influenced overall neurologic outcome. 
PATIENTS AND METHODS 
Patient selection. During a &year period extend- 
ing from February 1987 through August 1993, 1727 
patients with either unilateral or bilateral moderate 
(50% to 79% diameter-reducing) ICA stenosis as 
defined by color-flow duplex scanning (CFS) were 
identified from the cerebrovascular registry in the 
two accredited noninvasive vascular laboratories 
affiliated with the Section of Peripheral Vascular 
Surgery at Southern Illinois University School of 
Medicine, Springfield, Ill. Two hundred seventy-two 
patients (15.7%) underwent follow-up CFS one or 
more additional times unrelated to the development 
of neurologic symptoms and constitute the base 
population for this study. To reduce the possibiliv of 
bias in our patient selection, patients were excluded 
from this study if they received a second follow-up 
scan as a result of the development of new symptoms, 
if they received a second scan but were noted to have 
a less than 50% diameter-reducing stenosis by CFS, 
and if they did not receive a second follow-up scan 
regardless of whether they had development of 
symptoms after their initial scan. In addition, patients 
with recurrent carotid artery stenosis after CEA were 
excluded from the study. Patients with stenoses of the 
contralateral ICA were included, but in no case did 
the degree of narrowing of this vessel exceed 50% to 
79%. 
Patients were separated into three groups, symp- 
tomatic, nonhemispheric, and asymptomatic, a cord- 
ing to their clinical presentation at the time of initial 
scanning. Indications for CFS in 87 patients in the 
"symptomatic" group were transient ischemic attacks 
(TIA), amaurosis fugax (AF) or stroke (cerebrovas- 
cular accident [CVA]). The "nonhemispheric" group 
consisted of 43 patients with vertebrobasilar o  
ill-defined cerebrovascular symptoms. One hundred 
forty-two patients in the "asymptomatic" group 
underwent CFS to investigate cervical bruits, to 
evaluate the ICAs before major abdominal or cardio- 
thoracic surgery, and as part of follow-up studies after 
a contralateral CEA. 
Follow-up. Most patients were referred to the 
vascular laboratories by community physicians, on 
whose discretion the timing and frequency of 
follow-up scans also depended. At the initial scan 
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Table II. Neurologic events during follow-up 
Symptomatic (n = 87) Nonhemispheric (n = 43) Asymptomatic (n = 142) 
No. (%) No. (%) No. (%) 
Total events 23 (26.4) 17 (39.5) 30 (21.1) 
Localizing events 20 (23.0) 7 (16.3) 22 (15.5) 
Ipsilateral 13 (14.9) 7 (16.3) 14 (9.9) 
CVA 9 (10.3) 1 (2.3) 7 (4.9) 
TIA/AF 4 (4.6) 6 (14.0) 7 (4.9) 
Contralateral 7 (8.0) 0 (0.0) 8 (5.6) 
CVA 5 (5.7) 0 (0.0) 6 (4.2) 
TIA/AF 2 (2.3) 0 (0.0) 2 (1.4) 
Nonhemispheric events 3 (3.4) 10 (23.3) 8 (5.6) 
each patient was questioned about recent and remote 
cerebrovascular events, current medications, and risk 
factors for atherosclerosis. Follow-up clinical data 
were derived from hospital charts and clinic notes, 
vascular laboratory files, autopsy reports from local 
county offices, and through a telephone question- 
naire. 
Color-flow duplex scanning. Color-flow studies 
were performed with Quantum QAD I and 2000 
Angiodynographs (Siemens Medical Systems, Inc., 
Issaquah, Wash.). All patients were examined by 
experienced vascular laboratory technicians using 
established techniques. Criteria for identifying mod- 
erate ICA stenosis have been previously described in 
our vascular laboratory and are based on peak systolic 
and end diastolic velocities together with additional 
data derived from the B-mode image and spectral 
waveform analysis, s'6 Progression of disease was 
defined as an increase from a 50% to 79% stenosis to 
either an 80% to 99% stenosis or to complete 
occlusion of the ICA. (Percentage stenosis refers to 
the ratio of the diameter of the lumen at the point of 
maximal narrowing to that of the unobstructed distal 
ICA. 2) 
Statistical analysis. Definitive study endpoints 
were TIA, AF, stroke (CVA), or death. TIAs were 
defined as unilateral neurologic deficits lasting less 
than 24 hours, whereas AF was defined as transient 
monocular loss of vision. Any localizing neurologic 
deficit persisting for more than 24 hours was 
classified as a CVA. Nonhemispheric symptoms were 
also recorded. Proportional information between and 
within the study groups were compared by use of 
Fisher's exact test. Life-table analysis was used to 
determine cumulative survival and neurologic out- 
comes for patients in both symptomatic and asymp- 
tomatic groups. The log rank test was used to 
compare life-table differences. Ap value less than 0.05 
was considered statistically significant. Thirty-four 
(39%) of the patients in the symptomatic group, 12 
(28%) of the patients in the nonhemispheric group, 
and 34 (24%) of the patients in the asymptomatic 
group underwent CEA. These patients were censored 
for fife-table analysis and were excluded from further 
evaluation at the time of surgery. 
Risk factor influence on stroke risk was analyzed 
by separating patients into three previously described 
categories, low risk (0 to 5 factors), moderate risk (6 
risk factors), and high risk ( _> 7 risk factors).2 The risk 
factors included age greater than 70 years, male sex, 
a history of stroke, a history of smoking, hyperten- 
sion, diabetes mellitus, peripheral vascular disease, 
atrial fibrillation, myocardial infarction, hyperlipid- 
emia, and no aspirin intake. 
RESULTS 
Patient characteristics and risk factors are outlined 
in Table I. The three groups, symptomatic, nonhemi- 
spheric, and asymptomatic, were well matched for 
age, sex, and risk factors. The average number of 
follow-up color-flow duplex scans was 2.4 _+ 1.7 per 
patient (range 1 to 11), and the average follow-up 
period with scans was 26.3 _+ 15.5 months (range 1 
to 76 months). Complete clinical follow-up was 
obtained on 269 (98.8%) of the 272 patients at an 
average duration of 43.5 _+ 15.4 months (range 11 
to 82 months). 
Neurologic events. Table II lists the (new) 
neurologic events that occurred uring follow-up. 
With the exception of nonhemispheric events, which 
were more frequent (p < 0.002) in patients diag- 
nosed with nonhemispheric symptoms than they 
were in the symptomatic and asymptomatic groups, 
there were no significant differences among the three 
groups. 
Life-table analysis of total neurologic events 
(excluding nonhemispheric events), ipsilateral local- 
izing neurologic events, and ipsilateral stroke rates 
are shown in Tables III, IV, and V and are depicted 
in Figs. 1, 2, and 3. Neurologic events occurred at an 
average annual rate of about 11% in the symptomatic 
group, 8% in the nonhemispheric group, and 7% in 
the asymptomatic group. At 4 years, the total event 
rate in patients in the symptomatic group (43.5%) 
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Table III. Neurologic event-free rates* 
Non-event deaths + no. 
No. at No. of surviving incomplete 
Interval risk events interval 
No. lost to Interval Cumulative SE 
follow-up (%) (%) (%) 
Symptomatic 
1 month 87 3 17 
6 months 67 1 7 
1 year 59 4 9 
2 years 46 6 12 
3 years 28 4 10 
4 years 14 1 4 
5 years 9 1 8 
Nonhemispheric 
1 month 43 0 4 
6 months 39 1 1 
1 year 37 2 10 
2 years 25 1 9 
3 years 15 1 6 
4 years 8 1 4 
5 years 3 1 2 
Asymptomatic 
1 month 142 1 12 
6 months 129 3 10 
1 year 115 7 16 
2 years 92 3 20 
3 years 69 6 28 
4 years 34 1 25 
5 years 8 0 6 
0 96.2 96.2 2.0 
0 98.4 94.7 2.7 
0 92.7 87.7 4.0 
0 85.0 74.6 5.5 
0 82.6 61.6 7.2 
0 91.7 56.5 10.0 
0 80.0 45.2 11.2 
0 100.0 100,0 0.0 
0 97.4 97.4 2.5 
1 93.8 91.3 4.4 
0 95,1 86.9 6.3 
0 91.7 79.6 9.3 
0 83.3 66.4 13.6 
0 50.0 33.2 15.7 
0 99,3 99.3 0.7 
1 97.6 96.9 1.5 
0 93.5 90.5 2.6 
0 96.3 87.2 3.3 
1 89.0 77.6 4,4 
0 95.4 74.0 6.5 
0 100.0 74,0 13.3 
~Excludes nonhemispheric events. 
Table IV. Ipsilateral stroke/TIA-free rates 
Non-event deaths + no. 
No. at No. of surviving incomplete 
Interval risk events interval 
No. lost to Interval Cumulative SE 
fol~w-up (%) (%) (%) 
Symptomatic 
1 month 87 2 17 
6 months 68 0 8 
1 year 60 2 11 
2 years 47 6 12 
3 years 29 2 12 
4 years 15 0 6 
5 years 9 1 8 
Nonhemispheric 
1 month 43 0 4 
6 months 39 1 1 
1 year 37 2 10 
2 years 25 1 9 
3 years 15 1 6 
4 years 8 1 4 
5 )rears 3 1 2 
Asymptomatic 
1 month 142 0 12 
6 months 130 1 12 
1 year 116 4 18 
2 years 94 2 22 
3 years 70 6 29 
4 years 34 0 25 
5 years 9 0 7 
0 97.5 97.5 1.7 
0 100.0 97.5 1.9 
0 96.3 93.9 3.0 
0 85.4 80.1 5.2 
0 91.3 73.2 7.0 
0 100.0 73.2 9.8 
0 80.0 58.5 12,6 
0 100.0 100,0 0.0 
0 97.4 97.4 2.5 
1 93.8 91.3 4.4 
0 95.1 86.9 6.3 
0 91.7 79.6 9.3 
0 83.3 66,4 13.6 
0 50.0 33.2 15.7 
0 100.0 100.0 0.0 
1 99.2 99.2 0.8 
0 96.3 95.6 1,9 
0 97.6 93.2 2.5 
1 89.1 83.0 4.1 
0 100.0 83,0 5.9 
0 100.0 83.0 11.4 
was significantly (p = 0.05) greater than that in the 
asymptomatic group (26.0%). When analysis was 
restricted to total ipsilateral events, the 2-year ate in 
patients in the symptomatic group (19.9%) was 
significantly ~ = 0.03) higher than that in the 
asymptomatic group (6.8%). The average annual rate 
of ipsilateral events was approximately 7% in the 
symptomatic, 8% in the nonhemispheric, and 4% in 
the asymptomatic groups. At 2 years, the ipsilateral 
stroke rate in patients in the symptomatic group was 
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Fig. 1. Cumulative rates of all new neurologic events (ipsilateral nd bilateral, but excluding 
nonhemispheric events) for patients with moderate (50% to 79%) stenosis. Patients are 
classified according to their initial presentation i to symptomatic, nonhemispheric, and 
asymptomatic groups. See Table III for standard errors. 
12.9% compared with 3.8% in the asymptomatic 
group (p = 0.08). Based on 4-year ates of 22.6% in 
patients in the symptomatic group and 9.0% in 
patients in the asymptomatic group, the average 
annual stroke rate was: 5.7% in patients in the 
symptomatic group and 2.3% in patients in the 
asymptomatic group. Only one patient in the non- 
hemispheric group had a stroke, and this occurred 5
years after entry into the study. 
Disease progression. Serial CFS detected disease 
progression i  14 patients (16.1%) with symptom- 
atic disease. There were 10 patients (11.5%) whose 
stenosis progressed from 50% to 79% to 80% to 
99% and four (4.6%) who went on to complete ICA 
occlusion. Two patients who had development of
severe stenosis experienced TIAs; the other eight had 
no new symptoms. Of the patients who progressed to
complete occlusion, two remained symptom free, 
one was symptom free but had development of a 
stroke 1 month later, and one had a stroke at the time 
of occlusion. All localizing symptoms were ipsilateral 
to the disease progression. 
Progression occurred in seven (16.3%) of the 
nonhemispheric group. Two of the four patients 
whose disease progressed to 80% to 99% stenosis 
were symptom free and two had nonhemispheric 
symptoms. Two of the three patients who had 
development of total ICA occlusion had nonhemi- 
spheric symptoms and one had an ipsilateral TIA. 
In the patients in the asymptomatic group, 24 
(16.9%) had documented disease progression, 21 
(14.8%) to a severe stenosis, and 3 (2.1%) to 
complete ICA occlusion. Development of severe 
stenosis was accompanied by symptoms in eight 
patients; four had strokes, three had TIAs, and one 
had nonhemispheric symptoms. One of the four 
patients with stroke was initially symptom free after 
disease progression was first detected and another 
experienced nonhemispheric complaints before com- 
pleting a stroke. Of the three patients who advanced 
to total occlusion, two had a stroke. One of these 
patients was also initially symptom free at the time 
the occlusion was detected. Again, all localizing 
symptoms were ipsilateral to the disease progression. 
Total neurologic events (including contralateral 
and nonhemispheric events) were statistically more 
frequent (p = 0.01) in symptom-free patients with 
disease progression ( 10 of 24, 41.7%) than they were 
in those with stable disease (20 of 118, 16.9%). 
Similarly, the incidence of ipsilateral events was 
significantly higher (p = 0.00002) in symptom-free 
patients with disease progression (9 of 24, 37.5%) 
than it was in patients vdth stable disease (5 of 118, 
4.2%). Strokes also occurred more often (p = 
0.0001) in symptom-free patients with disease pro- 
gression (6 of 24, 25.0%) than they did in patients in 
whom no progression was detected (1 of 118, 
0.85%). On the other hand, in the initially symp- 
tomatic group, the incidence of overall neurologic 
events in patients with disease progression (4 of 14, 
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Fig. 2. Cumulative rates of new ipsilateral ischemic events (TIA, AF, and stroke) for patients 
with moderate (50% to 79%) stenosis. Patients are classified according to their presentation 
into symptomatic, nonhemispheric, and asymptomatic groups. Cumulative rates of symptom- 
atic and asymptomatic groups differed significantly (p = 0.03) at 2 years. See Table IV for 
standard errors. 
28.6%) was almost identical to that in patients with 
stable disease (19 of 73, 26.0%). The ipsilateral 
neurologic event and ipsilateral stroke rates were 
28.6% (four of 14) and 14.3% (two of 14), 
respectively, for patients in the symptomatic group 
with disease progression compared with 12.3% (nine 
of 73) and 9.6% (seven of 73) in those with no 
progression (p = 0.21 andp = 0.63). Patients in the 
nonhemispheric group with disease progression had 
a higher total neurologic event rate (5 of 7, 71.4%) 
than did patients with stable disease (11 of 36, 
30.6%) (2 = 0.08). The incidence of localizing 
symptoms, however, was almost identical in patients 
in the nonhemispheric group with or without pro- 
gressing disease. 
The average time for disease progression to 80% 
to 99% stenosis was 20.3 _+ 14.4 months (range 2to 
61 months). Development oftotal occlusion took an 
average of 27.5 _+ 15.5 months (range 3 to 55 
months). Rates of disease progression were similar in 
the three groups. 
Risk factors. The effect of risk factors on the 
incidence of stroke was investigated in a subset of 
patients who were monitored for 2 or more years. 
Patients with symptoms in the moderate and high- 
risk categories (six or more risk factors) had a 
significantly higher incidence of CVA (29.3%, 12 of 
41) than patients in the lower risk category (five or 
fewer isk factors), whose stroke incidence was 6.5% 
(two of 31) (p = 0.02). Similarly, although not quite 
to the same extent, patients in the asymptomafic 
group in the moderate and high-risk categories were 
noted to have a higher CVA rate (15.8%, nine of 57) 
than patients in the lower risk category, who had an 
incidence of 6.9% (four of 58) (2 = 0.15). The only 
stroke in the nonhemispheric group occurred in a 
patient with six or more risk factors. 
Mortality. During follow-up, 14 patients in the 
symptomatic group (16.1%), 9 patients in the 
nonhemispheric group (20.9%), and 20 patients in 
the asymptomatic group (14.1%) died (2 = 0.56). 
By life-table analysis (Table VI and Fig. 4), patients 
in the asymptomatic group had a slightly better 
survival rate than patients in the symptomatic or 
nonhemispheric group at all intervals during the 
study, but the differences did not reach statistical 
significance (2 > 0.41). Causes of death in both 
groups are shown in Table VII. Overall, stroke and 
heart disease accounted for 70% of the deaths. 
DISCUSSION 
That CEA reduces the risk of stroke in patients 
with symptomatic high-grade (70% to 99% 
diameter-reducing) stenoses of the ICA is well 
established. The NASCET study showed that the 
cumulative risk of ipsilateral stroke at 2 years in 
patients with hemispheric or retinal TIAs or nondis- 
abling stroke was 9% in the surgical group and 26% 
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Fig. 3. Cumulative rates of new ipsilateral strokes for patients with moderate (50% to 79%) 
stenosis. Patients are classified according to their initial presentation i to symptomatic, 
nonhemispheric, and asymptomatic groups. See Table V for standard errors. 
in the group receiving optimal medical therapy? Risk 
reduction with CEA correlated with the severity of 
stenosis, being greatest in patients with 90% to 99% 
stenosis (26%) and being least in the group with 70% 
to 79% stenosis (12%). 
The ECST study also came to a similar conclusion 
(medical risk 22%, surgical risk 12%, at 3 years); and, 
in addition, showed that CEA was not beneficial in 
patients with symptoms who had mild (1% to 29%) 
stenoses. 1 Whether patients with symptoms and 
moderate stenosis (diameter reduction in the 30% to 
69% range) derive any benefit from CEA remains to 
be demonstrated. Recruitment of this category of 
patients continues in both the NASCET and ECST 
studies, and results are expected to be forthcoming in 
1996 or 1997. Although the VA cooperative study of 
patients with symptomatic disease found that CEA 
reduced stroke or crescendo TIAs from 26% to 
8% when stenoses were greater than 70%, there was 
no difference in the outcomes of surgically (7.1%) 
and medically (6.7%) treated patients in a small 
number of patients with 50% to 69% stenosis at a 
mean follow-up time of 12 months. 7 This study 
was prematurely terminated on publication of the 
NASCET and ECST results. 
A number of studies upport he use of CEA to 
treat high-grade ICA stenoses in symptom-free 
patients, 81~ but there is little information regarding 
the risk of asymptomatic lesions or the benefits of 
surgery in the moderate (50% to 79%) stenosis 
range. Although the VA cooperative study of 
symptom-free patients with 50% to 99% stenosis of 
the ICA reported that CEA reduced the combined 
incidence ofipsilateral TIA and CVA from 20.6% to 
8.0%, the surgical results were not stratified accord- 
ing to degree of stenosis? Similar results were also 
published by Moore et al.,12 but again moderate and 
severe asymptomatic stenoses were combined in the 
analysis. According to a Clinical Advisory from the 
National Institutes of Health (September 28, 1994), 
the Asymptomatic Carotid Atherosclerosis Study 
Group, 13 report a 5-year stroke rate of 10.6% in 
medically treated patients with ICA stenoses of 60% 
to 99%. Chambers and Norris 14 found that the 
cumulative incidence of neurologic events exceeded 
20% at 3 years in medically treated, symptom free 
patients with greater than 75% stenosis compared 
with a less than 10% event rate in patients with 30% 
to 74% stenosis. No data, however, were provided on 
the 50% to 74% subset. 
With the advent of duplex scanning, an increasing 
number of patients with moderate carotid artery 
stenoses are being identified (almost 2000 in our 
laboratories during the course of this study). Clearly, 
some of these patients are at risk for development of
a stroke. What is the natural history of patients with 
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Tab le  V.  Ips i lateral  s t roke- f ree rates 
Non-stroke deaths + no. 
No. at No. of surviving incomplete No. lost to Interval Cumulative SE 
Interval risk strokes interval follow-up (%) (%) (%) 
Symptomatic 
1 month 87 0 i8 0 100.0 100.0 0.0 
6 months 69 0 8 0 100.0 100.0 0.0 
1 year 61 2 11 0 96.4 96.4 2.3 
2 years 48 4 13 0 90.4 87.1 4.5 
3 years 31 1 13 0 95.9 83.6 6.! 
4 years 17 1 7 0 92.6 77.4 8.9 
5 )Tears 9 1 8 0 80.0 61.9 12.7 
Nonhemispheric 
1 month 43 0 4 0 100.0 I00.0 0.0 
6 months 39 0 1 0 100.0 100.0 0.0 
1 year 38 0 10 1 100.0 100.0 0.0 
2 years 27 0 11 0 100,0 100.0 0.0 
3 years 16 0 8 0 100.0 100.0 0,0 
4 years 8 0 5 0 100.0 100.0 0.0 
5 years 3 1 2 0 50.0 50,0 20,4 
Asymptomatic 
1 month 142 0 12 0 t00.0 100.0 0.0 
6 months 130 1 12 1 99.2 99.2 0.8 
1 year 116 2 18 0 98.1 97.3 1.5 
2 years 96 1 23 0 98.8 96.2 !,9 
3 years 72 3 32 1 94.6 91.0 3.2 
4 years 36 0 26 0 100.0 91.0 4.6 
5 years 10 0 7 0 100.0 91.0 8.6 
Tab le  V I .  Surv ival  rates 
No. of No. surviving incomplete No. lost to Interval Cumulative SE 
Interval No. at risk deaths interval follow-up (%) (%) (%) 
Symptomatic 
1 month 87 i 17 0 98.7 98.7 1.2 
6 months 69 1 7 0 98.5 97.2 2,0 
I year 61 3 8 0 94.7 92.1 3.3 
2 years 50 2 14 0 95.4 87.8 4.3 
3 years 34 3 12 0 89.3 78.4 6.3 
4 years 19 3 7 0 80.7 63.2 8.8 
5 years 9 1 8 0 80.0 50.6 !I .9 
Nonhemispheric 
1 month 43 0 4 0 100,0 100.0 0.0 
6 months 39 1 0 0 97.4 97.4 2.5 
1 year 38 2 9 i 94.0 91.6 4.3 
2 years 27 5 6 0 79.2 72.5 7.3 
3 years 16 0 8 0 100.0 72.5 9.5 
4 years 8 1 4 0 83.3 60.4 13.4 
5 years 3 0 2 0 100.0 60.4 22.0 
Asymptomatic 
1 month 142 0 12 0 100.0 100.0 0.0 
6 months 130 2 10 1 98.4 98.4 1,1 
1 year 117 3 17 0 97,2 95.7 !.8 
2 years 97 5 20 0 94.3 90.2 2.9 
3 years 72 7 26 1 88.0 79.4 4.3 
4 years 38 2 25 0 92.3 73,2 6.2 
5 years 1I 1 7 0 86.7 63.4 i1.6 
th is  degree  o f  stenosis ;  how shou ld  they  be t reated;  
and  are there  gu ide l ines  to  ident i fy  those  most  at risk? 
Shou ld  pat ients  who do  not  undergo  operat ion  be 
mon i to red  w i th  serial  scans, and,  i f  so, how often? 
These  are some o f  the  quest ions  that  need  to  be 
answered .  
Over  an  average fo l low-up  per iod  o f  44  months ,  
we found an  annua l  tota l  neuro log ic  event  rate o f  
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Fig. 4. Cumulative survival rates for patients with moderate (50% to 79%) stenosis. Patients 
are classified according to their initial presentation i to symptomatic, nonhemispheric, and 
asymptomatic groups. See Table VI for standard errors. 
Table VII. Causes of death 
Cause of death Symptomatic Nonhemispheric Asymptomatic p Value 
Stroke 7 (50%) - 6 (30%) 0.04 
Heart (related) 4 (29%) 5 (56%) 8 (40%) 0.43 
Cancer 1 (7%) - 3 (15%) 0.41 
Other 2 (14%) 4 (44%) 3 (15%) 0.15 
p = 0.12 for total table, 
11% in patients with 50% to 79% ICA stenosis who 
presented initially with symptoms, an 8% rate in 
patients with nonhemispheric symptoms, and a 7% 
rate in symptom-free patients. About half of these 
events, however, were localized to the contralateral 
hemisphere or were nonhemispheric, anobservation 
that has been made by others. 15 The annual incidence 
of ipsilateral stroke was about 5.7% in the patients in 
the symptomatic group, 2.3% in the symptom-free 
patients, and 1.9% in the combined asymptomatic 
and nonhemispheric groups. Patients in the symp- 
tomatic group with 50% to 79% stenosis had a 
cumulative ipsilateral stroke rate of 12.9% and 
22.6% at 2 and 4 years, respectively, - considerably 
lower than the 26% rate at 2 years for medically 
treated patients with 70% to 99% stenosis reported 
in the NASCET study. 2Symptom-free patients with 
50% to 79% stenosis had a cumulative total ipsilat- 
eral event rate of 17.0% at 3 years, almost double that 
reported by Chambers and Norris 14 for stenoses 
between 30% and 74%. This suggests hat stenoses of 
30% to 49% are less risky than those in the higher 
category. 
Mortality rates did not differ significantly among 
the symptomatic, nonhemispheric, and asymptom- 
atic groups, reflecting the similar distribution of risk 
factors in the three groups. As previous eries have 
shown, heart disease was the most common cause of 
death, but almost one third of the deaths were 
attributable tostroke. During the course of the study, 
8.0% of the patients in the symptomatic group and 
4.2% of the patients in the asymptomatic group died 
of stroke. As in the NASCET study, 2the number of 
risk factors appeared to correlate with the incidence 
of stroke, but only in patients who initially had 
symptoms. 
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Although the rate of disease progression i  the 
three patient groups was nearly identical (about 
16%), patients in the symptomatic and nonhemi- 
spheric groups experienced a somewhat higher per- 
centage of total occlusions. The time required to 
progress t?om moderate stenosis to complete occlu- 
sion varied widely (3 to 55 months) but averaged 
about 2 years. Four of the 10 patients who had 
development of total occlusion of the ICA had a 
stroke, two of which were not preceded by a TIA. 
Similarly, Moneta et al. 8 reported that five of nine 
strokes in their series of medically treated patients 
with asymptomatic 80% to 99% stenoses occurred in 
conjunction with occlusion. None of the patients had 
a warning TIA. Others have also noted the rarity of 
premonitory TIAs in symptom-free patients who 
have development of strokes. 9'I5 
In a prospective study of symptom-free patients, 
Roederer et al. ~6 found progression to greater than 
80% stenosis was highly correlated with the devel- 
opment of total occlusion or new symptoms. Subse- 
quently, a number of other reports have confirmed 
the high risk of stroke and other neurologic events in 
association with progression of low- and moderate- 
grade lesions to severe stenoses. ~4a5 In our series, 21 
initially symptom-free patients progressed to have 
severe (80% to 99%) stenosis over an average of 20 
months. Eight (38%) had symptoms (4 strokes, 3 
TIAs, and 1 nonhemispheric), but two of the strokes 
occurred after disease progression was identified. 
Eighty-three percent (98/118) of our patients with 
asymptomatic moderate carotid artery disease who 
did not experience ipsilateral disease progression re-- 
mained symptom free over the period of the study. 
Ipsilateral neurologic events occurred in only five of 
these patients (4.2%), and only one (0.85%) had 
development of a stroke. Thus, in the absence of 
disease progression, moderate asymptomatic lesions 
appeared to have a relatively benign prognosis. 
Similarly, only one (2.8%) of 36 patients in the 
nonhemispheric group with stable disease had a 
stroke, and this stroke occurred 5 years after the initial 
SCan. 
In the VA study, medically treated patients with 
50% to 75% ICA stenoses had nearly the same rate 
of ipsilateral neurologic events (19.2%) as patients 
with 76% to 99% stenosis (22.4%). 3Both groups 
had stroke rates of about 9%. However, patients were 
not monitored for disease progression; and it is 
possible therefore that many of the moderate stenoses 
had progressed to a more severe category before 
symptoms developed. 
Although the accuracy of carotid artery duplex 
scanning has been questioned, it has proved to be 
reliable in our hands. As determined by an ongoing 
quality assurance program, our sensitivity., specificig-, 
and positive and negative predictive values for the 
detection of moderate and high-grade ICA stenosis 
and total occlusion of the ICA exceeded 90% 
throughout the period of the study. ~'6 Before being 
included in the study, all patients were required to 
have at least two scans confirming the presence of 
50% to 79% stenosis. Like all retrospective studies, 
our study may suffer from a selection bias in that 
repeat scans were ordered by referring physicians, 
who may have been prompted to do so by the 
occurrence of symptoms. To reduce this source of 
error, we included only those patients who had at 
least wo follow-up scans in the absence of any new 
symptoms. In addition, we surveyed 100 randomly 
selected patients from the group who had undergone 
a single duplex scan and had had no follow-up 
studies. There were 14 patients with strokes, nine 
with TIAs, four cases of AF, and two with nonhemi- 
spheric symptoms. Thirteen patients had died, three 
after a documented stroke. Thus the frequency mad 
distribution of neurologic events in this randomly 
selected cohort seemed to parallel that of our 
follow-up study. 
Our study suggests that most patients with mod- 
erate stenoses who are initially symptom free or have 
nonhemispheric symptoms remain symptom free and 
do not require CEA. A subgroup, however, have 
disease progression, which is frequently accompanied 
by important neurologic symptoms. Once patients 
experience new symptoms, their natural histo U 
changes, and they are more likely to have further 
neurologic events. Most distressingly, strokes are not 
preceded by herald TIAs in the majoriD ~ of patients. 
Clearly, the challenge is to identify those patients who 
are at greatest risk and offer them early CEA.17 Unfor- 
tunately, serial duplex scanning may not be the total 
answer, because the initial event may be complete 
occlusion, and progression to a more severe stenosis 
is frequently noted only after a stroke occurs and not 
before. Isa6 Moreover, because disease progression is 
usually abrupt, it may be impractical to reduce the 
interval between scans sufficiently to avoid missing a 
critical change. Nonetheless, we were able to detect 
disease progression before a stroke or total occlusion 
occurred in 79% (19/24) of our patients with advanc- 
ing stenosis. These patients are candidates for CEA. 
If CEA can be performed with an operative 
mortality and morbidity rate of 5% or less and if the 
yearly stroke rate thereafter does not exceed 1% to 
2%, then our study suggests hat CEA should benefit 
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patients in the symptomatic group with moderate 
disease, regardless o f  whether they experience disease 
progression? 8'19 Unless the ongoing prospective 
randomized trials demonstrate otherwise, CEA 
should be offered to patients with moderate stenoses 
who have appropriate symptoms, especially those 
with multiple risk factors, recurrent TIAs, or TIAs 
while receiving aspirin therapy. 19 
In conclusion, this study attempts to define the 
natural history o f  patients both with and without 
symptoms o f  moderate carotid artery stenosis. Al- 
though the risk o f  neurologic events with these le- 
sions is somewhat less than that associated with more 
severe disease, they are still potentially dangerous. 
Patients with symptoms should be considered for 
endarterectomy, and patients with no symptoms or 
nonhemispheric symptoms require careful follow-up. 
We thank Mary Garfield, BS, MT(ASCP), for her 
assistance in data storage and compilation and the Depart- 
ment of Statistics and Research Consulting of Southern 
Illinois University for their aid in data analysis. 
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DISCUSSION 
Dr. Robert W. Hobson I I  (Newark, N.J.). The data 
in this study were generated retrospectively, with its widely 
acknowledged methodologic pitfalls. Nevertheless, the 
information constitutes an important current database for 
the selection of patients for CEA for the moderate stenosis 
group. Obviously, the identification of subsets in a group 
with 2% and 4% annualized stroke rates is desirable as we 
identify patients for operation. These data will be valuable 
pending publication of prospectively-generated data from 
patients in the symptomatic group in a NASCET trial and 
patients in the asymptomatic group in the Asymptomatic 
Carotid Atherosclerosis Study Group trial. 
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In addition to severity of stenosis, these investigators 
have identified progression of disease to higher grade 
stenosis or occlusion as an important risk factor in the 
moderate stenosis group. However, it is more significant 
among symptom-free patients. Because the data from the 
VA trial on asymptomatic stenosis has identified also a 
subset of about 20% of patients with neurologic events, 
this subset analysis is most important. Although we have 
advocated use of the 50% stenosis as a threshold for 
considering CEA, subset analysis will more clearly sharpen 
and identify patients who will benefit from operations. 
Other risk factors not considered in the authors' 
analysis might also have included such things as ultrasonic 
plaque structure; the incidence of ulceration; the incidence 
of computed tomography (CT)-confirmed silent cerebral 
infarction; and status of collateral perfusion. 
Do you have any additional data on subset analysis 
regarding ultrasonic plaque structure, regarding the inci- 
dence of CT-confirmed silent cerebral infarction, or collat- 
eral cerebral perfusion? And when present, were they 
associated with increased neurologic event rates? 
Fascinating natural history, data are also presented by 
the authors on the risks of heart- or stroke-related mortality, 
rates. In two recently published similar analyses from the 
VA symptomatic group, we analyzed multiple risk factors 
and identified particularly high-risk combination of diabe- 
tes mellitus, abnormal electrocardiography results, and 
peripheral vascular insufficiency as being associated with a 
greater than 50% mortality rate, 60% of which was related 
to coronary artery disease over the 4-year mean clinical 
follow-up. 
Although you reviewed the number of risk factors from 
a group of 11 variables in your manuscript, which 
combination of specific factors do you regard as most 
important in the prediction of cardiac and neurologic 
events ? 
Finally, can you outline for us your clinical recommen- 
dations for preoperative cardiac workup in these patients 
selected for CEA? Who, if any, should undergo cardiac 
stress testing? Who should undergo cardiac atheterization 
and coronary artery intervention before CEA? 
Dr. M. AshrafMansour. Although we usually record 
the surface characteristics and echogenicity of carotid artery 
plaques as part of our laboratory protocol, we did not 
investigate the effect of plaque structure on development of
symptoms or disease progression i this study. The number 
of patients who underwent routine CT scanning was 
insufficient o determine the incidence of silent cerebral 
infarction or its effect on neurologic events. We found that 
in the aggregate the number of risk factors correlated with 
the incidence of stroke, but we did not determine the 
relationship of individual risk factors to adverse neurologic 
events. We are, however, in the process of examining the 
role of risk factors by a multivariate analysis. Finally, with 
regard to clinical recommendations for cardiac evaluation, 
we work closely with our cardiologists to weigh the 
possible risk of coronary artery disease. In patients who 
have few risk factors, we proceed with endarterectomy 
without further workup. In sedentary patients with mul- 
tiple risk factors, echocardiograms or thallium stress tests 
are obtained; and in patients with symptomatic coronary 
artery disease, coronary angiography is considered. Only a 
few patients require preoperative coronary angioplasty or 
concomitant coronary artery bypass grafting. 
Dr. William J. Quifiones-Baldrich (Los Angeles, 
Calif.). You have identified disease progression in this 
group of patients as an indicator of increased risk of stroke. 
But in your presentation, I noted that most of the patients 
who had disease progression had already had an event, 
many of them a stroke. Therefore my question is were you 
able to identify disease progression before or after the event 
occurred? If  the latter is the case, then, from a clinical point 
of view, it's too late in some of these patients if they already 
have had a stroke. 
Dr. Mansour. It is important hat surveillance detect 
disease progression before a stroke occurs. In our asymp- 
tomatic group, progression to greater than 80% diameter 
reduction was detected in 19 (79%) of 24 patients before 
a stroke occurred or the internal carotid artery occluded. 
For this reason, we believe that routine follow-up is 
valuable. 
Dr. Quifiones-Baldrich. Why didn't some of those 
patients undergo CEA when we know that progression to 
a higher degree of stenosis by the NASCET findings would 
indicate considering CEA? 
Dr. Mansour. In this study, decisions regarding 
therapy were made by the referring physicians. We had no 
control over the frequency of follow-up or on treannent. 
However, 69% of the patients with advancing disease did 
undergo CEA. 
Dr. Bruce M. Smith. (Washington, D.C.). You 
excluded a huge number of patients from your data, more 
than 1000, as I saw it. Do you have any information on the 
natural history of those excluded patients' performance 
with further neurologic events? 
Dr. Mansour. Because we were concerned about the 
possibility of a selection bias, we contacted a random 
sample of 100 patients with 50% to 79% stenoses who had 
not undergone follow-up duplex scanning. In this group of 
patients, the incidence of stroke, TIAs, AF, and death was 
practically identical to that in patients who had undergone 
further studies. Therefore we believe that the results we 
have reported are representative of the entire cohort of 
patients with moderate carotid artery disease. 
